SCHEMBL24512477

SCHEMBL24512477

Cc1ccc(-c2nnc(-c3ccccc3)[nH]2)cc1SNC1CCC2(CC1)OCCO2

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.33
KDM4E B2RXH2 3/20 0.33
HCRTR1 O43613 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 3/20 0.33
LMNA P02545 3/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
POLB P06746 2/20 0.31
GAA P10253 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30
ATM Q13315 1/20 0.30
HSD17B10 Q99714 1/20 0.30
KMT2A Q03164 1/20 0.30
CSF1R P07333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24512231 0.78 BRD4 (0.47) KMT2A
SCHEMBL29717155 0.78 BRD4 (0.47) KMT2A
SCHEMBL24512299 0.78 ALDH1A1 (0.39) L3MBTL1KDM4EHCRTR1ALDH1A1HPGD
SCHEMBL24512287 0.75 ALDH1A1 (0.36) L3MBTL1KDM4EHCRTR1ALDH1A1HPGD
SCHEMBL24512341 0.73 LMNA (0.33) L3MBTL1KDM4EHCRTR1ALDH1A1HPGD
SCHEMBL29717098 0.69 POLB (0.49) L3MBTL1KDM4EALDH1A1HPGDLMNA
SCHEMBL24512238 0.69 POLB (0.49) L3MBTL1KDM4EALDH1A1HPGDLMNA
SCHEMBL24512323 0.68 CNR1 (0.40) L3MBTL1KDM4EHCRTR1ALDH1A1HPGD
SCHEMBL24512285 0.66 NPY5R (0.38) L3MBTL1KDM4EHCRTR1ALDH1A1LMNA
SCHEMBL24512480 0.66 POLB (0.36) L3MBTL1MAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022125989-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS SCRIPPS RESEARCH INSTITUTE, THE (US) 2022-06-16 WO disclosed